← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Qrono, Inc
Pittsburgh, PA
$4,090,801
Total funding
7
Grants
Funding over time
peak $1.5M · FY2013–25$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,090,801 · 7
By mechanism
N44$1,498,252 · 1
N43$1,420,955 · 3
R41$1,171,594 · 3
Investigators at Qrono, Inc
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
IGF::OT::IGF FAILED TUBULIN INHIBITOR REFORMULATED AS LOCALIZED ADJUVANT THERAPY FOR HEAD AND NECK CANCER$1,498,252
N44 · FY2016 · CA
SCREENING FOR TOLEROGENIC ADJUVANTS TO ENHANCE ANTIGEN SPECIFIC IMMUNOTHERAPY FOR CELIAC DISEASE.$599,945
N43 · FY2023 · AI
APC SPECIFIC MTOP INHIBITION POTENTIATES IMMUNE RESPONSE TO IIV IN ELDERLY RECIPIENTS.$597,598
N43 · FY2022 · AI
Restoring Tolerance with an Oral AMPK Agonist Nanomedicine Targeting Intestinal Dendritic Cells as a Preventative Therapy for Type 1 Diabetes$306,500
R41 · FY2024 · AI
Restoring Tolerance in Inflammatory Bowel Disease with an Oral AMPK agonist Nanomedicine that Targets Antigen Presenting Cells.$306,468
R41 · FY2024 · DK
Restoring Tolerance in Inflammatory Bowel Disease with an Oral AMPK agonist Nanomedicine that Targets Antigen Presenting Cells.$302,409
R41 · FY2025 · DK
A New In Silico Design Platform for Building Custom Controlled Release Systems$256,217
R41 · FY2013 · GM
Failed tubulin inhibitor reformulated as localized adjuvant therapy for head and neck cancerPOP: 09/12/2014-06/11/2015$223,412
N43 · FY2014 · CA